MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Clinical trials for MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION explained in plain language.
Never miss a new study
Get alerted when new MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION trials appear
Sign up with your email to follow new studies for MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart surgery sedative may shield aging brains from memory loss
Disease control Recruiting nowThis study tests whether a sedative called dexmedetomidine can prevent long-term memory and thinking problems after heart surgery. About 2,400 adults aged 60 and older having planned heart surgery will receive either dexmedetomidine or standard care. Researchers will check their …
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Phase: PHASE4 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated May 17, 2026 10:11 UTC
-
Could one blood thinner be safer than two for older heart patients?
Disease control Recruiting nowThis study looks at whether using just one blood thinner (single antiplatelet therapy) is safer and as effective as using two (dual antiplatelet therapy) in older adults or those at high risk of bleeding who have had a heart procedure with a drug-coated balloon. About 576 partici…
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Phase: NA • Sponsor: Fondazione Ricerca e Innovazione Cardiovascolare ETS • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New injection aims to smooth neck bands in major trial
Symptom relief Recruiting nowThis study tests an injection called NT 201 (a type of botulinum toxin) to see if it safely reduces the appearance of prominent neck bands (platysma prominence) in adults. About 300 people with moderate to severe neck bands will receive either NT 201 or a placebo. The goal is to …
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Phase: PHASE3 • Sponsor: Merz North America, Inc. • Aim: Symptom relief
Last updated May 17, 2026 10:06 UTC
-
New drug HNK shows promise for Treatment-Resistant depression in early trial
Symptom relief Recruiting nowThis study tests a new drug called (2R,6R)-HNK to see if it can quickly improve symptoms in people with major depression that hasn't responded to other treatments. About 50 adults aged 18 to 70 will receive four infusions of HNK and four of a placebo over several weeks, with thei…
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Phase: PHASE2 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Symptom relief
Last updated May 15, 2026 12:07 UTC
-
New injection may smooth neck bands in major trial
Symptom relief Recruiting nowThis study tests an injection called NT 201 (a type of botulinum toxin) against a placebo in 300 adults with moderate to severe neck band prominence. The goal is to see if it safely reduces the appearance of these bands. Participants will be followed for several weeks, and those …
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Phase: PHASE3 • Sponsor: Merz Aesthetics GmbH • Aim: Symptom relief
Last updated May 11, 2026 20:51 UTC
-
NIH launches study to unlock secrets of mood disorder treatments
Knowledge-focused Recruiting nowThis study aims to learn more about how depression, bipolar disorder, and suicide risk affect people and how treatments work. Researchers will follow 500 adults already receiving care at the NIH, using interviews, questionnaires, and optional tests like blood draws and brain scan…
Matched conditions: MOLECULAR MECHANISMS OF PHARMACOLOGICAL ACTION
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC